Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$2.8 - $5.46 $288,120 - $561,834
-102,900 Reduced 53.79%
88,393 $256,000
Q4 2022

Feb 14, 2023

SELL
$2.85 - $5.18 $526,446 - $956,839
-184,718 Reduced 49.13%
191,293 $627,000
Q3 2022

Nov 14, 2022

BUY
$2.85 - $8.73 $1.07 Million - $3.28 Million
376,011 New
376,011 $1.42 Million
Q2 2022

Aug 08, 2022

SELL
$4.69 - $9.84 $149,362 - $313,374
-31,847 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$8.44 - $16.89 $268,788 - $537,895
31,847 New
31,847 $296,000
Q1 2020

May 15, 2020

SELL
$5.69 - $17.78 $58,038 - $181,356
-10,200 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$10.89 - $16.79 $111,078 - $171,258
10,200 New
10,200 $168,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $720M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.